TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

Benzinga Logo Benzinga By Vandana Singh
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

GSK reported strong Q3 results with sales of $11.53 billion, an 8% increase at constant currency. The company raised its 2025 financial guidance, expecting sales growth of 6-7% and core earnings per share increase of 10-12%.

Insights
ROST   neutral

Listed as a top holding with $244.6 million allocation, no specific performance details provided


GSK   positive

Strong quarterly performance, raised financial guidance for 2025, growth in specialty medicines and vaccine sales, and CEO's optimistic outlook for 2026